Wounded Warrior partnership aims to improve PTSD, TBI diagnosis

The Wounded Warrior Project and Cohen Veterans Bioscience recently announced the Research Alliance for PTSD/TBI Innovation and Discovery Diagnostics, a shared initiative to improve diagnosis and treatment of PTSD and traumatic brain injury.

“Identifying biomarkers is an important step in care for PTSD and [traumatic brain injury (TBI)],” Mike Richardson, vice president of mental health and independence services at Wounded Warrior Project, said in a press release. “We can better target treatment to individual patients and see improved results.”

The collaboration between Research Alliance for PTSD/TBI Innovation and Discovery Diagnostics (RAPID-Dx) and Warrior Care Network aims to expand research on biomarkers, and as a result improve the diagnosis and treatment of PTSD and TBI.

“RAPID-Dx will provide vital information for the precision treatment of patients with PTSD and TBI,” Magali Haas, MD, PhD, CEO of Cohen Veterans Bioscience, said in the release. “This partnership represents a best-in-class approach to helping the thousands of veterans in need, as well as others affected by these debilitating injuries.”

For more information:

To learn more about the Wounded Warrior Project, visit http://newsroom.woundedwarriorproject.org/about-us.

To support and learn about research from Cohen Veterans Bioscience, visit www.cohenveteransbioscience.org.

The Wounded Warrior Project and Cohen Veterans Bioscience recently announced the Research Alliance for PTSD/TBI Innovation and Discovery Diagnostics, a shared initiative to improve diagnosis and treatment of PTSD and traumatic brain injury.

“Identifying biomarkers is an important step in care for PTSD and [traumatic brain injury (TBI)],” Mike Richardson, vice president of mental health and independence services at Wounded Warrior Project, said in a press release. “We can better target treatment to individual patients and see improved results.”

The collaboration between Research Alliance for PTSD/TBI Innovation and Discovery Diagnostics (RAPID-Dx) and Warrior Care Network aims to expand research on biomarkers, and as a result improve the diagnosis and treatment of PTSD and TBI.

“RAPID-Dx will provide vital information for the precision treatment of patients with PTSD and TBI,” Magali Haas, MD, PhD, CEO of Cohen Veterans Bioscience, said in the release. “This partnership represents a best-in-class approach to helping the thousands of veterans in need, as well as others affected by these debilitating injuries.”

For more information:

To learn more about the Wounded Warrior Project, visit http://newsroom.woundedwarriorproject.org/about-us.

To support and learn about research from Cohen Veterans Bioscience, visit www.cohenveteransbioscience.org.